Effects of long-term PFM administration on serum hormones, inflammatory factors and enzymes associated with hypertension. (a) for angiotensin I (Ang I), (b) for angiotensin II (Ang II), for (c) for aldosterone (ALD), (d) for norepinephrine (NE), (e) for endothelin-1(ET-1), (f) for interleukin-6 (IL-6), (g) for tumor necrosis factor-α (TNF-α), (h) for interferon-β (IFN-β) and (i) for interleukin-1β (IL-1β). Values are expressed as mean ± SD (n = six rats). *** indicates p < 0.001, compared with the W control group; #, ## and ### indicate p < 0.05, p < 0.01 and p < 0.001, respectively, compared with the L-NAME control group. cont W: animals not treated with L-NAME receiving standard chow; cont LN: L-NAME treated rats receiving standard chow; LN + SR37-3: L-NAME treated rats receiving PFM-SR37-3; and LN + SR61-2: L-NAME treated rats receiving PFM-SR61-2.